对EGFR-TKI耐药NSCLC的免疫疗法:机制,治疗策略和新出现的挑战
Shuyi Hu1, Xinhong Shi1, Qin Hu1
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
表皮生长因子受体 (EGFR) 突变在非小细胞肺癌 (NSCLC) 中很常见. 本综述涵盖了EGFR突变NSCLC在EGFR氨酸激酶抑制剂 (EGFR-TKI) 和免疫治疗上进展的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 表皮生长因子受体 (EGFR) 突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 第三代EGFR氨酸激酶抑制剂 (EGFR-TKI) 是EGFR突变NSCLC的主要治疗方法.
- 了解瘤微环境对于治疗疗效至关重要.
研究的目的:
- 审查EGFR-TKI治疗后进展的NSCLC患者的治疗选择.
- 在这个人群中探索免疫疗法耐药机制和管理策略.
- 讨论结合EGFR-TKI和免疫治疗后的进展模式和随后的治疗方法.
主要方法:
- 对当前的治疗选择进行系统审查.
- 免疫疗法耐药性机制的概述.
- 讨论进展模式和随后的治疗方法.
主要成果:
- 对于EGFR突变性NSCLC来说,EGFR-TKI是至关重要的.
- 对EGFR-TKI的抗性需要探索替代策略.
- 免疫疗法耐药性机制需要特殊的管理方法.
结论:
- 基于耐药性,分子分析和进展模式的治疗算法可以指导临床决策.
- 有效管理EGFR突变NSCLC需要对顺序疗法的综合方法.
- 需要进一步研究克服对EGFR-TKI和免疫治疗的耐药性.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Mitogens and the Cell Cycle
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
